Conjugated Via Claimed Linking Group, Bond, Or Coupling Agent Patents (Class 424/194.1)
-
Patent number: 8192743Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.Type: GrantFiled: July 25, 2008Date of Patent: June 5, 2012Assignee: Enzon Pharmaceuticals, Inc.Inventors: Hong Zhao, Richard B. Greenwald, Susan L. Adler, legal representative
-
Patent number: 8187607Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: GrantFiled: October 8, 2008Date of Patent: May 29, 2012Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer
-
Patent number: 8183338Abstract: The invention provides a sterically hindered polymers and conjugates formed therefrom that comprise a water-soluble and non-peptidic polymer backbone having at least one terminus covalently bonded to an alkanoic acid or alkanoic acid derivative prior to conjugation, wherein the carbon adjacent to the carbonyl group of the acid or acid derivative group has an alkyl or aryl group pendent thereto. The steric effects of the alkyl or aryl group allow greater control of the hydrolytic stability of polymer derivatives. The polymer backbone may be poly(ethylene glycol).Type: GrantFiled: May 3, 2011Date of Patent: May 22, 2012Assignee: Nektar TherapeuticsInventors: Michael D. Bentley, Xuan Zhao, Xiaoming Shen, Lihong Guo
-
Patent number: 8173601Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.Type: GrantFiled: February 1, 2008Date of Patent: May 8, 2012Assignee: Acceleron Pharma, Inc.Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
-
Publication number: 20120107303Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.Type: ApplicationFiled: January 14, 2011Publication date: May 3, 2012Inventors: Ekambar R. Kandimalla, Sudhir Agrawal, Daqing Wang, Lakshml Bhagat, Dong Yu
-
Patent number: 8168195Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-DGalpNAc-(1?2)-?-D-PerpNAc-(1?3)-?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.Type: GrantFiled: May 22, 2009Date of Patent: May 1, 2012Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Shousun Chen Szu, John B. Robbins, Edward Konadu, Yvonne Ageyman Konadu, legal representative
-
Publication number: 20120100174Abstract: The present invention provides an immunogenic composition comprising one or more Streptococcus uberis sortase-anchored surface proteins, or an immunogenic part thereof, wherein the composition is capable of eliciting an immune response, when administered to a subject.Type: ApplicationFiled: October 6, 2009Publication date: April 26, 2012Applicant: THE UNIVERSITY OF NOTTINGHAMInventor: James Leigh
-
Patent number: 8153114Abstract: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.Type: GrantFiled: August 24, 2011Date of Patent: April 10, 2012Assignee: CytherisInventors: Michel Morre, Brigitte Assouline, Iann Rance, Anne Gregoire, Corinne Breque
-
Patent number: 8153140Abstract: The invention provides an immunogenic composition comprising MSP-8 linked to an antigen. Methods of using the composition to induce an immune response in an animal are also provided.Type: GrantFiled: April 19, 2011Date of Patent: April 10, 2012Assignee: Philadelphia Health and Education CorporationInventor: James M. Burns, Jr.
-
Publication number: 20120076817Abstract: Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Inventors: Che-Hung Robert Lee, Carl E. Frasch
-
Publication number: 20120076831Abstract: The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions.Type: ApplicationFiled: January 20, 2010Publication date: March 29, 2012Inventors: Stephen Miller, Russell L. Bromley, Michael A. Pleiss, Daniel Getts, Aaron Martin
-
Publication number: 20120070493Abstract: Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed.Type: ApplicationFiled: August 23, 2011Publication date: March 22, 2012Applicant: Selecta Biosciences, Inc.Inventors: CHRISTOPHER FRASER, Grayson B. Lipford, David H. Altreuter
-
Patent number: 8128942Abstract: The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to D. discoideum proteinase 1, as well as novel subunits thereof, and methods of making and using the conjugates in vaccines to treat sepsis and other infectious complications.Type: GrantFiled: May 21, 2010Date of Patent: March 6, 2012Assignee: EndoBiologics, IncorporatedInventors: Gary L. Gustafson, Dan C. DeBorde
-
Patent number: 8124590Abstract: The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier.Type: GrantFiled: June 19, 2007Date of Patent: February 28, 2012Assignee: Dynavax Technologies CorporationInventors: Gary Van Nest, Stephen F. Tuck, Karen L. Fearon, Dino Dina
-
Publication number: 20120039926Abstract: The conjugated peptide constructs described herein can be used to induce production of dendritic cells that generate cytokines. The vaccine-bearing dendritic cells can be administered to induce T cell mediated immune modulating responses.Type: ApplicationFiled: April 14, 2010Publication date: February 16, 2012Applicants: CEL-SCI CORPORATION, NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINEInventors: Kenneth S. Rosenthal, Daniel H. Zimmerman, Patricia R. Taylor
-
Publication number: 20120034259Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.Type: ApplicationFiled: September 10, 2008Publication date: February 9, 2012Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
-
Patent number: 8105608Abstract: A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cells by the host's immune response.Type: GrantFiled: November 16, 2005Date of Patent: January 31, 2012Assignee: Purdue Research FoundationInventors: Philip Stewart Low, Yingjuan Lu
-
Publication number: 20120021056Abstract: Described herein are methods and systems that can be used to induce immunologic tolerance to non-self antigens. The methods and systems comprise introducing a tolerogen comprising at least one immunogenic non-self antigen coupled to a carrier, wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. The non-self antigen can be selected from the group consisting of carbohydrate antigens, full-length antigenic proteins, and fragments and combinations thereof, while the carrier can be selected from nanoparticles and stents. Tolerogen compositions are also provided and can be used to induce immunologic tolerance to non-self antigens. These methods, systems and compositions are particularly advantageous since they can be used to allow for the extension of the window of safety for immunologically-incompatible transplantations to patients who are growing past the age of infancy.Type: ApplicationFiled: December 11, 2009Publication date: January 26, 2012Inventors: Lori Jeanne West, Todd Lambert Lowary, Jillian Mary Buriak, Brian Daly, Mylvaganam Jeyakanathan, Peter John Meloncelli, Vincent Arthur Wright, Anne Margaret Cooper
-
Publication number: 20120009254Abstract: Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes one or more polypeptide epitopes from RSV. Specifically, the multilayer films include two polypeptide epitopes from RSV, such as an epitope that elicits a specific T-cell response such as a cytotoxic T-cell response, and an epitope that elicits a specific antibody response.Type: ApplicationFiled: July 7, 2011Publication date: January 12, 2012Applicant: ARTIFICIAL CELL TECHNOLOGIES, INC.Inventors: Thomas J. Powell, James Gorham Boyd
-
Patent number: 8093046Abstract: The invention provides a recombinant multi-functional chimera of CVN and 12p1. Chimeras of CVN and 12p1 present a model for targeting gp120 at two discrete sites, by two different modes of inhibition and with increasing potency versus either component alone. A chimera of the invention combines the high affinity suppression of viral activity by CVN with the allosteric suppression of viral envelope binding to both CD4 and co-receptor by 12p1.Type: GrantFiled: May 31, 2007Date of Patent: January 10, 2012Assignee: Philadelphia Health and Education Corporation d/b/c Drexel University College of MedicineInventors: Karyn McFadden, Irwin M. Chaiken
-
Patent number: 8092805Abstract: Compounds, which inhibit the binding of gp120 to CD4 as well as 17b and methods for their use in inhibiting the HIV fusion process, are provided.Type: GrantFiled: December 15, 2009Date of Patent: January 10, 2012Assignee: Philadelphia Health and Education CorporationInventors: Hosahudya Gopi, Irwin Chaiken
-
Publication number: 20120003260Abstract: One aspect of the present invention relates to solution-phase approaches to GPI synthesis. Another aspect of the present invention relates to key building blocks, and syntheses thereof, useful for GPI assembly. Yet another aspect of the invention relates to an automated method for the synthesis of GPIs and fragments thereof.Type: ApplicationFiled: May 17, 2011Publication date: January 5, 2012Applicant: Massachusetts Institute of TechnologyInventors: Peter H. Seeberger, Michael C. Hewitt, Daniel Snyder
-
Patent number: 8088884Abstract: The present disclosure provides novel POZ-2 derivatives, methods for synthesizing POZ-2 derivatives and intermediates useful in such methods. In one embodiment, the POZ-2 derivative comprises two linear POZ chains of the present disclosure linked directly or indirectly to a branching moiety that contains a functional group for linking the POZ-2 derivative to the target molecule. Target molecule-POZ-2 conjugates are also described. In certain embodiment, the POZ-2 derivatives have low polydispersity values and a decreased amount of impurities produced by unwanted side reactions, such as, but not limited to, chain transfer.Type: GrantFiled: September 29, 2008Date of Patent: January 3, 2012Assignee: Serina Therapeutics, Inc.Inventors: J. Milton Harris, Michael David Bentley, Kunsang Yoon, Zhihao Fang
-
Publication number: 20110318382Abstract: An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5? exocyclic carbon of an adjacent subunit, (ii) is capable of uptake by monocytes, lymphocytes, and dendritic cells in a mammalian subject, (iii) contains between 10-40 nucleotide bases, and (iv) has a base sequence effective to hybridize to at least 12 contiguous bases of a target sequence contained in an exon-2 or exon-4 slice site region of human IL-10 pre-mRNA.Type: ApplicationFiled: June 22, 2011Publication date: December 29, 2011Applicant: AVI BIOPHARMA, INC.Inventors: Dan V. Mourich, Patrick L. Iversen
-
Patent number: 8080254Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.Type: GrantFiled: September 22, 2006Date of Patent: December 20, 2011Assignee: Amgen, Inc.Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pellymounter, Christopher Francis Toombs
-
Publication number: 20110305723Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: December 23, 2010Publication date: December 15, 2011Applicant: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
-
Publication number: 20110300173Abstract: Immunogenic compositions, and method of using the compositions to elicit an immune response against Campylobacter jejuni. The compositions are isolated polysaccharide polymers derived from Campylobacter jejuni capsule.Type: ApplicationFiled: May 27, 2011Publication date: December 8, 2011Inventors: Patricia Guerry, Mario Artur Monteiro
-
Publication number: 20110300174Abstract: The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.Type: ApplicationFiled: June 2, 2011Publication date: December 8, 2011Applicant: Pfizer Vaccines LLCInventors: Alan Daniel BROWN, Heather Lynn DAVIS, David P. GERVAIS, Lyn Howard JONES, James R. MERSON, David Cameron PRYDE, David R. STEAD, Michael J. MCCLUSKIE, Jennifer Marie THORN, Paul Robert MEHELIC, Parag Ashok KOLHE, Keshab BHATTACHARYA, Jari Ilmari FINNEMAN, Erin Kristen PARSONS, Nickolas ANASTASIOU
-
Patent number: 8067011Abstract: The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.Type: GrantFiled: April 9, 2007Date of Patent: November 29, 2011Assignee: Chimeros, Inc.Inventors: Claude Geoffrey Davis, Miguel A. de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
-
Publication number: 20110287048Abstract: Antigen specific regulatory T cells are described and related compositions, methods and systems. Methods to generate an antigen specific anti-inflammatory regulatory T cell is provided, the method comprising contacting either a T cell or an antigen presenting cell with a zwitterionic polysaccharide conjugated to the antigen for a time and under condition to generate an antigen specific regulatory T cell that is capable of inhibiting a pro-inflammatory response against the antigen.Type: ApplicationFiled: May 20, 2011Publication date: November 24, 2011Inventors: June L. Round, Sarkis K. Mazmanian
-
Patent number: 8062641Abstract: An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit through a 1,6-linkage which connects C-6 of the first unit to C-1 of the second unit, wherein the 1,6-linkage comprises a phosphonate. Related methods of making such compounds, analogous compounds, or intermediates thereof are also disclosed.Type: GrantFiled: May 8, 2006Date of Patent: November 22, 2011Assignees: Novartis AGInventors: Stefan Oscarson, Peter Teodorovic, Paolo Costantino
-
Publication number: 20110274713Abstract: The invention relates to compounds having formula (I): Scaffold-[L-(Antigen)t]y (I) wherein Antigen represents at least a portion of a target antigen for modulating an immune response; wherein t is 0 or an integer of at least 1; wherein y is at least 1; wherein the number of Antigens on the Scaffold is at least 2; wherein L is a linking group or a covalent bond, wherein when L is a covalent bond, the covalent bond is a single bond attached to a sp or sp2 hybridized atom of the Scaffold and when L is a linking group, the linking group is attached to the Scaffold through a single bond attached to a sp or sp2 hybridized atom; whereby the Scaffold is sufficiently rigid to maintain the relative position of the single bonds attached to sp or sp2 hybridized atoms. Further described are compositions containing the compounds and methods of using them.Type: ApplicationFiled: August 4, 2009Publication date: November 10, 2011Applicant: The University of QueenslandInventors: Paul Leslie Burn, Joanna T. Blanchfield, George Vamvounis, Yogendra Singh, Melissa Lee Foster
-
Publication number: 20110274714Abstract: The present invention is drawn to attenuated Salmonella serovar strains S. Typhimurium and S. Enteritidis, conjugate vaccines derived from these attenuated strains of S. Typhimurium and S. Enteritidis, comprising an O polysaccharide covalently linked to a flagellin protein, and methods for inducing an immune response in a subject comprising administering the attenuated strains and/or the conjugate vaccines of the invention.Type: ApplicationFiled: January 16, 2010Publication date: November 10, 2011Applicant: University of Maryland, BaltimoreInventors: Myron M. Levine, Raphael Simon, James Galen, Sharon Tennant
-
Publication number: 20110262479Abstract: Two-domain MHC polypeptides useful for manipulation of antigen-specific T-cells are disclosed. These polypeptides include MHC class II-based molecules that comprise covalently linked ?1 and ?1 domains, and MHC class I-based molecules that comprise covalently linked ?1 and ?2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, and to treat conditions mediated by antigen-specific T-cells.Type: ApplicationFiled: April 25, 2011Publication date: October 27, 2011Inventors: Gregory G. Burrows, Arthur A. Vandenbark
-
Patent number: 8039005Abstract: Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against S. pyogenes are useful in vaccine compositions to induce protection against S. pyogenes.Type: GrantFiled: February 24, 2010Date of Patent: October 18, 2011Assignee: Novartis AGInventors: Giuliano Bensi, Immaculada Margarit Y Ros, Emiliano Chiarot, Guido Grandi, Maria Scarselli
-
Patent number: 8026209Abstract: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain barrier functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides herein. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain barrier properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.Type: GrantFiled: February 10, 2004Date of Patent: September 27, 2011Assignee: BBB Holding B.V.Inventors: Pieter Jaap Gaillard, Albertus Gerrit De Boer, Arjen Brink
-
Publication number: 20110229511Abstract: Methods of neutralising circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs.Type: ApplicationFiled: October 2, 2009Publication date: September 22, 2011Inventors: Stephen Michael Henry, Caroline Ann Oliver
-
Patent number: 8012488Abstract: A novel polyoxyalkylene derivative represented by the following formula (1), wherein each symbol is as defined in the specification, which has a functional group capable of reacting with various physiologically active substances according to the object is provided.Type: GrantFiled: February 17, 2006Date of Patent: September 6, 2011Assignee: NOF CorporationInventors: Kenji Sakanoue, Kenichiro Nakamoto, Yuji Yamamoto, Hiroki Yoshioka
-
Publication number: 20110206757Abstract: The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein.Type: ApplicationFiled: January 31, 2011Publication date: August 25, 2011Applicant: Sloan Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Jennifer R. Allen, Govindaswami Ragupathi, Philip O. Livingston, Lawrence Williams
-
Publication number: 20110200632Abstract: The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.Type: ApplicationFiled: February 2, 2011Publication date: August 18, 2011Applicant: Lipotek Pty Ltd.Inventors: David C. Jackson, Christopher R. Parish
-
Patent number: 7988969Abstract: Compositions that include an A? polypeptide linked to a non-A? polypeptide are described, as well as methods of using such compositions.Type: GrantFiled: August 31, 2009Date of Patent: August 2, 2011Assignee: MAYO Foundation for Medical Education and ResearchInventors: Joseph F. Poduslo, Geoffry L. Curran
-
Patent number: 7972601Abstract: Provided are methods and compositions for treating autism spectrum disorders by administering an antioxidant or agent that stabilize or enhance expression of altered neuroligins. An aspect of the disclosure includes site-specific delivery of the antioxidant to the endoplasmic reticulum (ER) to reverse incorrect disulfide binding of the protein neuroligin. Also disclosed is a method of targeting the antioxidant to neuroligin by using the calcium binding or other recognition site of neuroligin to bind the antioxidant. The antioxidant can be cysteamine linked to a molecule which binds to a binding site.Type: GrantFiled: May 10, 2005Date of Patent: July 5, 2011Assignee: The Regents of the University of CaliforniaInventors: Palmer Taylor, Davide Comoletti, Lori Jennings, Robyn Flynn
-
Publication number: 20110159081Abstract: The present invention provides an immunogenic composition comprising at least one antigen delivery particle and at least one antigen, wherein the antigen and antigen delivery particle are linked using an intermediate linker.Type: ApplicationFiled: August 26, 2009Publication date: June 30, 2011Inventors: Ralph Leon Biemans, Abdelatif Elouahabi
-
Publication number: 20110150880Abstract: The invention relates to the compositions of synthetic oligo-?-(1?6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same.Type: ApplicationFiled: July 21, 2009Publication date: June 23, 2011Applicant: The Brigham and Women's Hospital, Inc.Inventors: Gerald B. Pier, Nikolay Nifantiev, Yury Tsvetkov, Marina Gening
-
Patent number: 7964196Abstract: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanocparticle drug delivery system is also provided.Type: GrantFiled: May 25, 2005Date of Patent: June 21, 2011Assignee: Chimeros, Inc.Inventors: Miguel de los Rios, Kenneth J. Oh
-
Patent number: 7960502Abstract: The invention provides a sterically hindered polymer that comprises a water-soluble and non-peptidic polymer backbone having at least one terminus covalently bonded to an alkanoic acid or alkanoic acid derivative, wherein the carbon adjacent to the carbonyl group of the acid or acid derivative group has an alkyl or aryl group pendent thereto. The steric effects of the alkyl or aryl group allow greater control of the hydrolytic stability of polymer derivatives. The polymer backbone may be poly(ethylene glycol).Type: GrantFiled: January 19, 2010Date of Patent: June 14, 2011Assignee: Nektar TheapeuticsInventors: Michael D. Bentley, Xuan Zhao, Xiaoming Shen, Lihong Guo
-
Patent number: 7951376Abstract: The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines.Type: GrantFiled: May 29, 2008Date of Patent: May 31, 2011Assignee: ImaxioInventors: Fergal Hill, Jean-Baptiste Marchand, Laurence Dumon
-
Patent number: 7951379Abstract: The invention provides a therapeutic drug that uses hollow protein nanoparticles displaying an antibody against a specific cell or specific tissue. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present invention, a substance to be transferred into a cell for treating a disease (for example, a cancer treating gene such as a thymidine kinase gene derived from simple herpes virus) is encapsulated in hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein that has been modified to lack its infectivity to hepatocytes and display an antibody). The particle surface of the drug displays an antibody, such as a cancer specific antibody, that recognizes an antigen molecule displayed on the surface of a specific cancer cell.Type: GrantFiled: March 26, 2003Date of Patent: May 31, 2011Assignees: Japan Science and Technology Agency, Beacle, Inc.Inventors: Shunichi Kuroda, Katsuyuki Tanizawa, Toshihide Okajima, Akihiko Kondo, Masakazu Ueda, Masaharu Seno
-
Patent number: 7947277Abstract: The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.Type: GrantFiled: September 7, 2007Date of Patent: May 24, 2011Assignee: Genentech, Inc.Inventors: James A. Ernst, Paul Polakis, Bonnee Rubinfeld, Venita I. DeAlmeida
-
Patent number: 7947279Abstract: The invention is directed to methods for increasing learning and memory in a subject with a neuropathological condition, specifically a condition related to elevated beta-amyloid deposition, the method comprising administering to the subject an effective amount of a compound capable of increasing the activity of Uch-L1. The invention is also directed to screening methods for identifying compounds that enhance the activity of the proteasome system, Uch-L1, or both.Type: GrantFiled: June 29, 2006Date of Patent: May 24, 2011Assignee: The Trustees of Columbia University in the City of New YorkInventors: Ottavio Arancio, Michael L. Shelanski, Bing Gong